Retatrutide
Triple GLP-1/GIP/glucagon agonist. Phase II trials show significant adipose reduction.
Index entry
Research context
Triple GLP-1/GIP/glucagon agonist. Phase II trials show significant adipose reduction.
How to read this entry
The current evidence grade is Phase II. It describes the strongest verified research stage represented in the record; it is not a statement of safety, efficacy or suitability for use.
Editorial scope
This entry is an evidence index, not medical guidance. Detailed mechanisms, open questions and primary references can be added through the structured editorial importer as the record is reviewed.